Advanced drug delivery system has opened novel approaches to develop the therapeutic effects of potentially-efficient molecules. Specifically, Lipid Nanoparticles (LNs) have recruited as promising Nano carriers in cancer therapy. LNs exhibit remarkable advantages such as reduced toxicity, high bioavailability of drugs, incorporation versatility of lipophilic and hydrophilic drugs, and large-scale production feasibility. Furthermore, LNs overcome numerous physiological barriers that prohibit drug delivery to tumor location and are also able to curb mechanisms of multidrug resistance, unique characteristics of cancer cells. E-cadherin (CDH1) is an epithelial cadherin, belongs to the calcium-dependent adhesion molecule superfamily, and is implicated in the interactions of hematopoietic progenitors and bone marrow stromal cells. Adhesion capacity to bone marrow stroma was impaired for leukemia cells, suggesting that a breakdown of adhesive mechanisms governed by an adhesion molecule may exist in the leukemic microenvironment. Our Nano formulation mainly consists of liposomal nanoparticles to deliver CDH1 for targeting leukemic cells. LNs can deliver CDH1 by different mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment. After the restoration of E-cadherin in leukemia cells, E-cadherin-specific adhesion was enhanced.
